Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Interprofessional Perspectives on Safety Management with Targeted Therapy for B-Cell Malignancies

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

Interprofessional Perspectives on Safety Management with Targeted Therapy for B-Cell Malignancies

In an educational program from PeerView and CLL Society, an interprofessional team comprised of a hematologist-oncologist (Anthony R. Mato), cardiologist (Dipti Gupta), oncology nurse (Kristen Battiato), and pharmacist (Amber C. King) take a close look at BTK and BCL-2 inhibitors in the B-cell cancer setting and discuss how they collaborate to manage toxicity and safety concerns associated with targeted therapies.

Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events.

This educational program is focused on a healthcare provider audience and eligible for CME credit, but we welcome patient viewers. You will need to complete a short quiz prior to watching the hour-long program.